EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer

Keila S Espinoza iD, Ashley J Snider iD

Cancers · 15.02.2024 · 16 (4) · 789

DOI: 10.3390/cancers16040789 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.02.2024. Verfasst von Keila S Espinoza und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, University of Arizona, Tucson, AZ 85721, USA. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institute for Diabetes and Digestive and Kidney Diseases at the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD), characterized by chronic inflammation in the intestinal tract, increases the risk for the development of colorectal cancer (CRC). Sphingolipids, which have been implicated in IBD and CRC, are a class of bioactive lipids that regulate cell signaling, differentiation, apoptosis, inflammation, and survival. The balance between ceramide (Cer), the central sphingolipid involved in apoptosis and differentiation, and sphingosine-1-phosphate (S1P), a potent signaling molecule involved in proliferation and inflammation, is vital for the maintenance of normal cellular function. Altered sphingolipid metabolism has been implicated in IBD and CRC, with many studies highlighting the importance of S1P in inflammatory signaling and pro-survival pathways. A myriad of sphingolipid analogues, inhibitors, and modulators have been developed to target the sphingolipid metabolic pathway. In this review, the efficacy and therapeutic potential for modulation of sphingolipid metabolism in IBD and CRC will be discussed.

Schlagwörter

Stichwörter der Autor:innen

ceramidecolitis-associated cancercolorectal cancerinflammationinflammatory bowel diseasesphingolipidssphingosine-1-phosphate

Autor:innen und Institutionen

  • Department of Physiology, University of Arizona, Tucson, AZ 85721, USA.
  • School of Nutritional Sciences and Wellness, University of Arizona, Tucson, AZ 85721, USA.
  • University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85721, USA.

ORCID-Profile: Keila S Espinoza, Ashley J Snider

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institute for Diabetes and Digestive and Kidney Diseases at the National Institutes of Health

Zitieren

APA

Espinoza, K. S., & Snider, A. J. (2024). Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer. Cancers, 16(4), 789. https://doi.org/10.3390/cancers16040789

Vancouver

Espinoza KS, Snider AJ. Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer. Cancers. 2024;16(4):789. doi:10.3390/cancers16040789

BibTeX
@article{Espinoza2024,
  author = {Espinoza, Keila S and Snider, Ashley J},
  title = {Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {4},
  pages = {789},
  doi = {10.3390/cancers16040789}
}
Kostenlos starten →